Krishnaswamy Yeleswaram Sells 20,225 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Key Points

• Insider sale: Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics on April 17 at an average price of $39.99 for $808,797.75, leaving him with 246,426 shares (a 7.58% reduction in his position valued at about $9.85M).
• Aggregate April selling: Yeleswaram sold a total of 40,450 shares across multiple April transactions (Apr 8–17), generating roughly $1.52 million in proceeds.
• Market context: RAPP traded around $36.95 with a 12‑month high/low of $42.27/$7.73 and carries a consensus analyst rating of "Buy" with a $53.83 price target.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 20,225 shares of the business's stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $39.99, for a total value of $808,797.75. Following the completion of the transaction, the insider owned 246,426 shares in the company, valued at $9,854,575.74. The trade was a 7.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Krishnaswamy Yeleswaram also recently made the following trade(s):

• On Tuesday, April 14th, Krishnaswamy Yeleswaram sold 10,200 shares of Rapport Therapeutics stock. The stock was sold at an average price of $35.08, for a total value of $357,816.00.
• On Monday, April 13th, Krishnaswamy Yeleswaram sold 9,165 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.97, for a total value of $320,500.05.
• On Friday, April 10th, Krishnaswamy Yeleswaram sold 500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.98, for a total value of $17,490.00.
• On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.90, for a total value of $12,564.00.

Rapport Therapeutics Price Performance

Shares of NASDAQ RAPP traded down $0.19 during midday trading on Tuesday, reaching $36.95. The company's stock had a trading volume of 428,604 shares, compared to its average volume of 345,939. Rapport Therapeutics, Inc. has a 12-month low of $7.73 and a 12-month high of $42.27. The firm has a 50 day moving average price of $30.52 and a 200-day moving average price of $28.63. The stock has a market capitalization of $1.77 billion, a P/E ratio of -12.92 and a beta of 1.09.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.07). On average, equities analysts predict that Rapport Therapeutics, Inc. will post -3.1 EPS for the current year.

Institutional Investors Weigh In On Rapport Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Strs Ohio raised its holdings in Rapport Therapeutics by 23.5% during the 3rd quarter. Strs Ohio now owns 2,100 shares of the company's stock valued at $62,000 after acquiring an additional 400 shares during the period. Russell Investments Group Ltd. raised its holdings in Rapport Therapeutics by 56.9% during the 4th quarter. Russell Investments Group Ltd. now owns 2,282 shares of the company's stock valued at $69,000 after acquiring an additional 828 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Rapport Therapeutics by 64.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock valued at $70,000 after acquiring an additional 905 shares during the period. Meeder Asset Management Inc. bought a new stake in Rapport Therapeutics during the 4th quarter valued at $37,000. Finally, Creative Planning raised its holdings in Rapport Therapeutics by 12.8% during the 3rd quarter. Creative Planning now owns 11,959 shares of the company's stock valued at $355,000 after acquiring an additional 1,357 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Raymond James Financial assumed coverage on shares of Rapport Therapeutics in a report on Friday, April 10th. They issued a "strong-buy" rating and a $66.00 price target on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. Wall Street Zen cut shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 14th. Truist Financial raised shares of Rapport Therapeutics to a "strong-buy" rating in a report on Wednesday, March 25th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Rapport Therapeutics in a report on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $53.83.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.